MARFLOXIN 5 MG TABLETS FOR CATS AND DOGS

国家: 爱尔兰

语言: 英文

来源: HPRA (Health Products Regulatory Authority)

有效成分:

MARBOFLOXACIN

可用日期:

Krka, d.d., Novo mesto

ATC代码:

QJ01MA93

INN（国际名称）:

MARBOFLOXACIN

剂量:

5 Milligram

药物剂型:

Tablets

处方类型:

POM

治疗组:

Canine, Feline

治疗领域:

Marbofloxacin

疗效迹象:

Antibacterial

授权状态:

Authorised

授权日期:

2013-05-03

产品特点

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Marfloxin 5 mg tablets for cats and dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablets.
Light brownish yellow, round, biconvex, marble tablets with bevelled
edges and with possible dark and white spots,
scored on one side.
The tablets can be divided into halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats and dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of infections caused by strains of microorganisms
susceptible to marbofloxacin.
In dogs:
skin and soft tissue infections (skinfold pyoderma, impetigo,
folliculitis, furunculosis, cellulitis);
urinary tract infections (UTI) associated or not with prostatitis or
epididymitis;
respiratory tract infections.
In cats:
skin and soft tissue infections (wounds, abscesses, phlegmons);
upper respiratory tract infections.
4.3 CONTRAINDICATIONS
Do not use in dogs aged less than 12 months, or less than 18 months
for exceptionally large breeds of dogs, such as
Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer
growth period.
Do not use in cats aged less than 16 weeks.
Do not use in animals with known hypersensitivity to marbofloxacin or
other (fluoro)quinolones or to any of the
excipients of the product.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
A low urinary pH could have an inhibitory effect on the activity of
marbofloxacin. Pyoderma occurs mostly secondary
to an underlying disease, thus, it is advisable to determine the
underlying cause and to treat the animal accordingly.
Each tablet contains:
ACTIVE SUBSTANCE:
Marbofloxacin
5 mg
EXCIPEINTS:
For a full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_